Takeda announced restructuring on March 25, 2026, affecting ~634 US employees, including 247 in Cambridge, Massachusetts (effective July 1, 2026–Dec 31, 2027).
Cuts aim to save >JPY 200B (~$1.25B) by FY2028 to fund launches like zasocitinib, oveporexton, rusfertide.
Part of ongoing layoffs:
~1,500 in 2024-early 2025, 137 in Oct 2025, 243 in Jan 2026.
No mention of targeting 4,500 jobs in recent announcements.